摘要
晚期卵巢癌多合并腹水,临床上单靠全身用药效果不甚满意.我们于1988年初开始应用以顺铂为主的联合化疗行腹腔注射治疗晚期卵巢癌合并腹水,取得了较好效果,有效率达90％.DDP是卵巢癌化疗的关键药物,腹腔内注入比静脉更具优点,浓度比静脉高25倍,对组织渗透性好,不引起腹腔局部中毒,副作用也较轻;且与其它药物无交叉耐药性,值得临床推广.
Most of the advanced ovarian cancer patients are accompanied by ascites which rarely responded tosystemic chemotherpy. Trial with DDP-combined chemotherapy regimen intraperitoneally in patients with advanced ovarian cancer with or without ascites was carried out since 1988 achieving response rate of 90%. The mainstay agent in this regimen was DDP. The drug concentration in ascitic fluid was 25 times that of the serum. No severe toxicity was noted. There was no drug cross-resistance.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
1994年第3期191-193,共3页
Chinese Journal of Clinical Oncology
关键词
癌
腹水
腹腔
卵巢肿瘤
顺铂
Ovarian cancer Intraperitoneal chemotherapy DDP containing regimen Ascites
